Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.27)
# 1,059
Out of 4,996 analysts
498
Total ratings
43.2%
Success rate
3.6%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $15.17 | +31.84% | 21 | Sep 18, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $67.42 | +18.66% | 34 | Sep 17, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $27.89 | +64.93% | 25 | Sep 9, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $31 → $34 | $26.59 | +27.87% | 2 | Sep 8, 2025 | |
| IMVT Immunovant | Reiterates: Buy | $35 | $16.23 | +115.65% | 23 | Sep 4, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $14 | $9.34 | +49.89% | 18 | Sep 3, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | $1 | $0.97 | +3.08% | 17 | Aug 29, 2025 | |
| EVO Evotec SE | Maintains: Buy | $8 → $7 | $3.48 | +101.15% | 10 | Aug 14, 2025 | |
| BHVN Biohaven | Maintains: Buy | $54 → $30 | $15.00 | +100.00% | 15 | Aug 12, 2025 | |
| EOLS Evolus | Maintains: Buy | $27 → $20 | $5.99 | +234.17% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $115 | $52.02 | +121.07% | 25 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $720 → $774 | $712.03 | +8.70% | 40 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $65.55 | +80.02% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $45.91 | +76.43% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.36 | +959.32% | 26 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $37.98 | +39.55% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.50 | +366.67% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $20.18 | +68.48% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $17.57 | +8.14% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.09 | +474.16% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.65 | +218.58% | 14 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.74 | +934.48% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $22.39 | +154.58% | 26 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $14.07 | +6.61% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.10 | +138.10% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.84 | +42,655.34% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.07 | +834.58% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $163.79 | +11.12% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.04 | +166.37% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $38.81 | -53.62% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $18.34 | -56.38% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $25.24 | +106.02% | 2 | Jun 11, 2019 |
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $15.17
Upside: +31.84%
Protagonist Therapeutics
Sep 17, 2025
Reiterates: Buy
Price Target: $80
Current: $67.42
Upside: +18.66%
Alkermes
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $27.89
Upside: +64.93%
Rapport Therapeutics
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $34
Current: $26.59
Upside: +27.87%
Immunovant
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $16.23
Upside: +115.65%
Rezolute
Sep 3, 2025
Reiterates: Buy
Price Target: $14
Current: $9.34
Upside: +49.89%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: $1
Current: $0.97
Upside: +3.08%
Evotec SE
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.48
Upside: +101.15%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $54 → $30
Current: $15.00
Upside: +100.00%
Evolus
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $5.99
Upside: +234.17%
Aug 5, 2025
Maintains: Buy
Price Target: $105 → $115
Current: $52.02
Upside: +121.07%
Aug 1, 2025
Maintains: Buy
Price Target: $720 → $774
Current: $712.03
Upside: +8.70%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $65.55
Upside: +80.02%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $45.91
Upside: +76.43%
Jun 11, 2025
Reiterates: Buy
Price Target: $25
Current: $2.36
Upside: +959.32%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $37.98
Upside: +39.55%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.50
Upside: +366.67%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $20.18
Upside: +68.48%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $17.57
Upside: +8.14%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $2.09
Upside: +474.16%
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $5.65
Upside: +218.58%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.74
Upside: +934.48%
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $22.39
Upside: +154.58%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $14.07
Upside: +6.61%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $2.10
Upside: +138.10%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.84
Upside: +42,655.34%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.07
Upside: +834.58%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $163.79
Upside: +11.12%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.04
Upside: +166.37%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $38.81
Upside: -53.62%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $18.34
Upside: -56.38%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $25.24
Upside: +106.02%